Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR-) Wistar rats

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2650-2656

  Leslie, Elaine M ^a,b   Ghibellini, Giulia ^a,c   Nezasa, Ken Ichi ^a,d   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ABC TRANSPORTER; CARBONYL DERIVATIVE; CARCINOGEN; CARRIER PROTEIN; CYTOCHROME P450; GLUCURONIDE; HYDROXYACID; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; TRITIUM;

ANIMAL TISSUE; ARTICLE; BILE DUCT; BILIARY EXCRETION; BIOTRANSFORMATION; BLOOD ANALYSIS; CANNULATION; CONTROLLED STUDY; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION; TOBACCO; URINALYSIS; WILD TYPE; WISTAR RAT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BILE DUCTS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CARCINOGENS; CYCLIC N-OXIDES; GLUCURONATES; MALE; NITROSAMINES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 36949011678     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm187     Document Type: Article

References (45)

1. Hecht,S.S. (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol., 11, 559-600.
2. Hecht,S.S. (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer, 3, 733-744.
3. Carmella,S.G. et al. (2002) Analysis of N-and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chem Res. Toxicol., 15, 545-550.
4. Morse,M.A. et al. (1990) Characterization of a glucuronide metabolite of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats. Carcinogenesis, 11, 1819-1823.
5. Carmella,S.G. et al. (1993) Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers'urine. Cancer Res., 53, 721-724.
6. Hecht,S.S. (1999) Tobacco smoke carcinogens and lung cancer. J. Natl Cancer Inst., 91, 1194-1210.
7. Jalas,J.R. et al. (2005) Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem. Res. Toxicol., 18, 95-110.
8. Zimmerman,C.L. et al. (2004) Stereoselective metabolism and tissue retention in rats of the individual enantiomers of 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanol (NNAL), metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carrinogenesis 25, 1237-1242.
9. Wu,Z. et al. (2002) Disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in bile duct-cannulated rats: Stereoselective metabolism and tissue distribution. Carcinogenesis, 23, 171-179.
10. Leslie,E.M. et al. (2005) Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 204, 216-237.
11. Leslie,E.M. et al. (2001) Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J. Biol. Chem., 276, 27846-27954.
12. Jedlitschky,G. et al. (2006) Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin. Drug Metab. Toxicol., 2, 351-366.
13. Nies,A.T. et al. (2007) The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch, 453, 643-659.
14. Zamek-Gliszczynski,M.J. et al. (2006) Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechamsms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci., 27, 447-486.
15. Paulusma,C.C. et al. (1997) The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J. Mol. Med., 75, 420-428.
16. Suzuki,H. et al. (1998) Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin. Liver Dis., 18, 359-376.
17. Kartenbeck,J. et al. (1996) Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology, 23, 1061-1066.
18. Schulze,J. et al. (1992) Biliary excretion of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the rat. Carcinogenesis, 13, 1961-1965.
19. Fleck,C. et al. (1990) Influence of xenobiotics on bile flow and bile composition in rats - methodologicaI approach. Exp. Pathol., 39, 175-185.
20. Cabral,A.D. et al. (1998) Central alpha2-receptor mechanisms contribute to enhanced renal responses during ketamine-xylazine anesthesia. Am. J. Physiol., 275, R1867-R1874.
21. Jansen,P.L. et al. (1985) Hereditary conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology, 5, 573-579.
22. Hecht,S.S. (2004) Carcinogen derived biomarkers: Applications in studies of human exposure to secondhand tobacco smoke. Tob. Control, 13 (suppl. 1), i48-i56.
23. Azzi,C. et al. (2006) Permeation and reservoir formation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (B[a]P) across porcine esophageal tissue in the presence of ethanol and menthol. Carcinogenesis, 27, 137-145.
24. Hecht,S.S. et al. (1993) Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: Pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis, 14, 229-236.
25. Meger,M. et al. (1999) Metabolism and disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in rhesus monkeys. Drug Metab. Dispos., 27, 471-478.
26. Millburn,P. et al. (1967) Biliary excretion of foreign compounds. Biphenyl, stilboestrol and phenolphthalein in the rat: Molecular weight, polarity and metabolism as factors in biliary excretion. Biochem. J. 105, 1275-1281.
27. Levine,W.G. (1978) Biliary excretion of drugs and other xenobiotics. Annu. Rev. Pharmacol. Toxicol., 18, 81-96.
28. Ninomiya,M. et al. (2006) Functional analysis of mouse and monkey multidrug resistance-associated protein 2 (Mrp2). Drug Metab. Dispos. 34, 2056-2063.
29. Ishizuka,H. et al. (1999) Species differences in the transport activity for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther., 290, 1324-1330.
30. Ninomiya,M. et al. (2005) Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in-comparison with rat Mrp2. Drug Metab. Dispos., 33, 225-232.
31. Zamek-Gliszczynski,M.J. et al. (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol. Pharmacol., 70, 2127-2133.
32. Zamek-Gliszczynski,M.J. et al. (2006) Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J. Pharmacol. Exp. Ther., 319, 459-467.
33. Chandra,P. et al. (2004) The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm. Res., 21, 719-735.
34. Ren,Q. et al. (1999) Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by rat UDP-glucuronosyltransferase 2B1. Drug Metab. Dispos., 27, 1010-1016.
35. Shelby,M.K. et al. (2003) Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab. Dispos., 31, 326-333.
36. Kiang,T.K. et al. (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther., 106, 97-132.
37. Ogawa,K. et al. (2000) Characterization of inducible nature of MRP3 in rat liver. Am. J. Phys., 278, G438-G446.
38. Chen,C. et al. (2004) Rat multidrug resistance protein 4 (Mrp4, Abcc4): Molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. Biochem. Biophys. Res. Commun. 317, 46-53.
39. Murphy,S.E. et al. (1995) Glucuronidation of 4-(hydroxymethyl)nitrosamino)-1-(3-pyridyl)-1-butanone, a metabolically activated form of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, by phenobarbital-treated rats. Chem. Res. Toxicol., 8, 772-779.
40. Hirohashi,T. et al. (1998) Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Mol. Pharmacol., 53, 1068-1075.
41. -) rats. J. Pharmacol. Exp. Ther., 295, 512-518.
42. -) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity. Biochem. Pharmacol., 70, 1832-1839.
43. Oswald,S. et al. (2006) Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J. Pharmacol. Exp. Ther., 318, 1293-1299.
44. Johnson,B.M. et al. (2006) Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab. Dispos., 34, 556-562.
45. - and EHBR rats. Life Sci., 77, 1106-1115.